Cancer researchers identify new metastasis suppressor gene

July 14, 2014

(Medical Xpress)—Among patients with deadly cancers, more than 90 percent die because of metastatic spread of their disease. Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, a research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tumors.

Activation of the PI3K/AKT signal pathway is a known driver of the progression of to the castrate-resistant stage, the most lethal form of prostate cancer. Using a genome-wide genetic screen, Dr. Gelman and colleagues identified a previously unknown metastasis suppressor—the FOXO4 protein, which belongs to a family of genes that are produced by all human cells.

"Evidence from several publicly available cancer genomic databanks indicates that FOXO4 is typically turned off in compared to primary prostate tumors. Our research showed that the FOXO4 gene normally turns off genes that control specific metastatic behavior in malignant tumor cells, such as the ability to invade tissues and then to survive and multiply there," says Dr. Gelman, the John & Santa Palisano Chair in Cancer Genetics at RPCI.

In demonstrating that FOXO4 works to prevent the spread of cancerous tumors by binding to and inhibiting the protein RUNX2, the team identified a circuit that controls metastatic progression in prostate cancer.

"Our findings underline the importance of RUNX2 in promoting metastasis and suggest that drugs that inhibit its function would prevent or treat prostate cancer metastasis," notes Dr. Gelman. "Given the devastating impact of cancer metastasis and the dire need for therapies to combat tumor spread, we're highly encouraged by these findings and excited about the therapeutic possibilities they open up."

Dr. Gelman's lab is now working with collaborators at the University of Maryland to test the effectiveness of the experimental agent CADD522, an inhibitor of RUNX2 function, in preventing or impeding prostate .

Explore further: COUP-TFII sparks prostate cancer progression

More information: Su B, Gao L, Baranowski C, Gillard B, Wang J, et al. (2014) "A Genome-Wide RNAi Screen Identifies FOXO4 as a Metastasis-Suppressor through Counteracting PI3K/AKT Signal Pathway in Prostate Cancer." PLoS ONE 9(7): e101411. DOI: 10.1371/journal.pone.0101411

Related Stories

COUP-TFII sparks prostate cancer progression

November 28, 2012

Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive ...

Stopping the spread of breast cancer

June 3, 2014

The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.